Predictive accuracy and usefulness of calibration of the ESC SCORE in Switzerland

European Journal of Preventive Cardiology

Volumn 15, Issue 4, 2008, Pages 402-408

  Marques Vidal, Pedro ^a,b   Rodondi, Nicolas ^c   Bochud, Murielle ^b   Pécoud, Alain ^c   Hayoz, Daniel ^d   Paccaud, Fred ^b   Mooser, Vincent ^f   Waeber, Gérard ^e   Vollenweider, Peter ^e  

^a CardioMet   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d Vascular Medicine   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f GLAXOSMITHKLINE   (United States)

Author keywords

cardiovascular disease; epidemiology; mortality; primary prevention; risk function

Indexed keywords

ACCURACY; ADULT; AGED; ARTICLE; CALIBRATION; CARDIOVASCULAR RISK; CROSS-SECTIONAL STUDY; FEMALE; HEART DEATH; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SWITZERLAND; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; MIDDLE AGED; STATISTICAL MODEL;

ADULT; AGED; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; RISK ASSESSMENT; RISK FACTORS; SWITZERLAND;

EID: 55249117985     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e3282fb040f     Document Type: Article

References (28)

1. Mackay J, Mensah GA. Atlas of heart disease and stroke. 1. Geneva. Switzerland: World Health Organization; 2004.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442.
3. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28: 2375–2414.
4. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002; 105: 310–315.
5. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.
6. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999; 353: 1547–1557.
7. Hartz I, Njolstad I, Eggen AE. Does implementation of the European guidelines based on the SCORE model double the number of Norwegian adults who need cardiovascular drugs for primary prevention? The Tromso study 2001. Eur Heart J 2005; 26: 2673–2680.
8. Buitrago Ramírez F, Cañón Barroso L, Díaz Herrera N, Cruces ME, Bravo Simón B, Perez Sánchez I. Comparación entre la tabla del SCORE y la función Framingham-REGICOR en la estimación del riesgo cardiovascular en una población urbana seguida durante 10 años [Comparison of the SCORE function chart and the Framingham-REGICOR equation to estimate the cardiovascular risk in an urban population after 10 years of follow-up]. Med Clin (Barc) 2006; 127: 368–373.
9. Maiques Galán A, Antón Garcia F, Franch Taix M, Albert Ros X, Aleixandre Martí E, Collado Gil A. Riesgo cardiovascular del SCORE comparado con el de Framingham. Consecuencias del cambio propuesto por las Sociedades Europeas [Cardiovascular risk of SCORE compared to Framingham. Consequences of the change proposed by the European Societies]. Med Clin (Barc) 2004; 123: 681–685.
10. Panagiotakos DB, Fitzgerald AP, Pitsavos C, Pipilis A, Graham I, Stefanadis C. Statistical modelling of 10-year fatal cardiovascular disease risk in Greece: the HellenicSCORE (a calibration of the ESC SCORE project). Hellenic J Cardiol 2007; 48: 55–63.
11. Sans S, Fitzgerald AP, Royo D, Conroy R, Graham I. Calibración de la tabla SCORE de riesgo cardiovascular para España [Calibrating the SCORE cardiovascular risk chart for use in Spain]. Rev Esp Cardiol 2007; 60: 476–485.
12. Levi F, Lucchini F, Negri E, La Vecchia VC. Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart 2002; 88: 119–124.
13. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehab 2003; 10: S1–S10.
14. Rodondi N, Cornuz J, Marques-Vidal P, Butler J, Hayoz D, Pecoud A, et al Aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland. Prev Med 2008; 46: 137–144.
15. El Assaad MA, Topouchian JA, Darne BM, Asmar RG. Validation of the Omron HEM-907 device for blood pressure measurement. Blood Press Monit 2002; 7: 237–241.
16. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989; 5: 255–268.
17. Lin LI. A note on the concordance correlation coefficient. Biometrics 2000; 56: 324–325.
18. Groupe de travail Lipides et Athérosclérose (GSLA). Score de l'ESC. Available at http://www.agla.ch/03_risiko/03_esc.php?spr=fr&rollover=3&rollnavi=2&rollspr=fr&sprtb=2007.28–3–2007.
19. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970–2002. JAMA 2005; 294: 1255–1259.
20. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623–1630.
21. Wing LM, Reid CM, Ryan P, Beilin U, Brown MA, Jennings GL, et al A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583–592.
22. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–1278.
23. Lutz JM, Pury P, Fioretta G, Raymond L. The impact of coding process on observed cancer mortality trends in Switzerland. Eur J Cancer Prev 2004; 13: 77–81.
24. Marrugat J, D'Agostino R, Sullivan L, Elosua R, Wilson P, Ordovas J, et al An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health 2003; 57: 634–638.
25. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med 2000; 342: 1–8.
26. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, et al Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 1995; 274: 131–136.
27. Biau DJ, Latouche A, Porcher R. Competing events influence estimated survival probability: when is Kaplan-Meier analysis appropriate? Clin Orthop Relat Res 2007; 462: 229–233.
28. Grunkemeier GL, Jin R, Eijkemans MJ, Takkenberg JJ. Actual and actuarial probabilities of competing risks: apples and lemons. Ann Thorac Surg 2007; 83: 1586–1592.